US4686237A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Erythro-(E)-7-[3'-C1-3 alkyl-1'-(3",5"-dimethylphenyl)naphth-2'-yl]-3,5-dihydroxyhept-6-enoic acids and derivatives thereof
Assignee: Novartis Pharmaceuticals Corp
•
Filing: 1986-02-19
•
Granted: 1987-08-11
•
Expires: 2006-02-19
Abstract
Abstract Compounds of the formula ##STR1## wherein R 1 is C 1-3 alkyl, and Z is ##STR2## wherein R 7 is hydrogen, R 8 or M, wherein R 8 is a physiologically acceptable and hydrolyzable ester group, and M is a pharmaceutically acceptable cation, the use thereof for inhibiting cholesterol biosynthesis and lowering the blood cholesterol level and, therefore, in the treatment of hyperlipoproteinemia and atherosclerosis, pharmaceutical compositions comprising such compounds and processes for and intermediates in the synthesis of such compounds.
Inventors
- 👤 Paul L. Anderson
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 15:57
CPC Classifications
C; C07; C07D; C07D309/00; C07D309/16; C07D309/28; C07D309/30; A; A61; A61K; A61K31/00; A61K31/185; A61K31/19; C07C; C07C59/00; C07C59/40; C07C59/42; C07C59/48
Claims Analysis
Total Claims: 16
Claim 1
Independent Claim
38 words
A compound of the formula ##STR18## wherein R 1 is C 1-3 alkyl, and R 7 is hydrogen, R 8 or M, wherein R 8 is a physiologically acceptable and hydrolyzable ester group, and M is a cation.
Claim 2
Dependent Claim
38 words
A compound of the formula ##STR18## wherein R 1 is C 1-3 alkyl, and R 7 is hydrogen, R 8 or M, wherein R 8 is a physiologically acceptable and hydrolyzable ester group, and M is a cation.
Claim 3
Dependent Claim
13 words
A compound according to claim 1 wherein M is a pharmaceutically acceptable cation.
Claim 4
Dependent Claim
23 words
A compound according to claim 2 wherein R 7 is hydrogen, C 1-3 alkyl or M, wherein M is a pharmaceutically acceptable cation.
Claim 5
Dependent Claim
14 words
A compound according to claim 3 wherein R 7 is a pharmaceutically acceptable cation.
Claim 6
Dependent Claim
11 words
A compound according to claim 4 wherein R 7 is sodium.
Claim 7
Dependent Claim
13 words
A compound according to claim 4 wherein R 1 is methyl or isopropyl.
Claim 8
Dependent Claim
11 words
A compound according to claim 6 wherein R 7 is sodium.
Claim 9
Dependent Claim
10 words
The compound according to claim 7 having the formula ##STR19##
Claim 10
Dependent Claim
10 words
The compound according to claim 3 having the formula ##STR20##
Claim 11
Dependent Claim
33 words
A pharmaceutical composition comprising an effective amount of a compound according to claim 2 and a harmaceutically acceptable carrier, said effective amount being an amount sufficient to inhibit cholesterol biosynthesis in a mammal.
Claim 12
Dependent Claim
32 words
A pharmaceutical composition according to claim 10 comprising an effective amount of the compound of the formula ##STR21## said effective amount being an amount sufficient to inhibit cholesterol biosynthesis in a mammal.
Claim 13
Dependent Claim
36 words
A method of inhibiting cholesterol biosynthesis comprising administering to a mammal in need of such treatment an effective amount of a compound according to claim 2, said effective amount being an amount effective for inhibiterol biosynthesis.
Claim 14
Dependent Claim
37 words
A method of treating atherosclerosis comprising administering to a mammal in need of such treatment an effective amount of a compound according to claim 2, said effective amount being an amount effective for the treatment of atherosclerosis.
Claim 15
Dependent Claim
29 words
A method of treating atherosclerosis according to claim 13 comprising administering to a mammal in need of such treatment an effective amount of a compound of the formula ##STR22##
Claim 16
Dependent Claim
41 words
A method of treating atherosclerosis according to claim 14 comprising administering to a mammal in need of such treatment an effective amount of the compound of the formula ##STR23## said effective amount being an amount effective for the treatment of atherosclerosis.
References Cited (Backward Citations)
US3983140A
Cited
US4198425A
Cited
US4248889A
Cited
US4255444A
Cited
US4375475A
Cited
US4351844A
Cited
EP0038061A1
Cited
US4361515A
Cited
US4308378A
Cited
US4440927A
Cited
US4376863A
Cited
US4387242A
Cited
BE895445A
Cited
US4474971A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1990-08-10 | 1991-02-09 | 1991-08-11 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1994-08-10 | 1995-02-09 | 1995-08-11 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1998-08-10 | 1999-02-09 | 1999-08-11 | $7700.00 | Window Closed / Lapsed |